Avastin plus PC demonstrated superior survival in first-line advanced nsNSCLC

In Study E4599, median OS with Avastin plus PC was 12.3 months vs 10.3 months with PC alone (HR=0.80 [95% CI, 0.68–0.94], P=0.013).[1]

nsNSCLC=non-squamous non-small cell lung cancer; OS=overall survival; PC=paclitaxel + carboplatin; HR=hazard ratio; CI=confidence interval.